Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis / 中华皮肤科杂志
Chinese Journal of Dermatology
;
(12): 170-173, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-885192
ABSTRACT
Interleukin (IL) -17A plays a key role in the occurrence and development of psoriasis. To date, several marketed IL-17A and its receptor antagonists have been applied to the treatment of psoriasis, and definite therapeutic effects have been achieved. However, several adverse reactions, including upper respiratory tract infection, Candida infections, neutropenia, inflammatory bowel disease, which can be life-threatening, have been reported in clinical trials and after marketing of these biologics. This review summarizes clinical safety profiles of 3 types of interleukin-17A and its receptor antagonists, i.e., secukinumab, ixekizumab and brodalumab.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Dermatology
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS